Thursday, July 9, 2026

Drug profile · INN

cilastatin sodium

cilastatin sodium (IMIPENEM AND CILASTATIN) is a renal dipeptidase inhibitor. Route of administration: intramuscular. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — cilastatin sodium
US status
approved
Class
Route
INTRAMUSCULAR
Patents
0
Programs
2
Data quality
0.84

Quick answer

cilastatin sodium (IMIPENEM AND CILASTATIN) is a renal dipeptidase inhibitor. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN cilastatin sodium
Brand IMIPENEM AND CILASTATIN
Mechanism Renal dipeptidase inhibitor
Target Dipeptidase 1
Route INTRAMUSCULAR
Formulation POWDER

Mechanism of action

Renal dipeptidase inhibitor

Primary target: Dipeptidase 1

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. SPR994-305 Phase 3 · Spero Therapeutics · complicated urinary tract infection (cUTI) or acute pyelonep
  2. Imipenem Approved · Chinese Academy of · Sepsis

Frequently asked questions

What is cilastatin sodium?

cilastatin sodium (IMIPENEM AND CILASTATIN) is a renal dipeptidase inhibitor. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for cilastatin sodium?

IMIPENEM AND CILASTATIN is a marketed brand name for cilastatin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cilastatin sodium?

cilastatin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.